Patents by Inventor Benjamin Berkhout

Benjamin Berkhout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8383364
    Abstract: Provided is an rtTA and single chain rtTA variants and uses thereof for inducible expression of a nucleic acid of interest. Nucleic acid molecules comprising an improved rtTA and/or sc rtTA sequence according to the invention are also provided, as well as vectors, replicons and cells comprising such nucleic acid molecules.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: February 26, 2013
    Assignee: TET Systems GmbH & Co. KG
    Inventors: Benjamin Berkhout, Atze Taede Das
  • Publication number: 20120178671
    Abstract: The inventors surprisingly found that specific oligosaccharides are capable of inhibiting viral replication through inhibiting NF-?B activation. The invention thus pertains to a composition comprising pectin (in the form of digalacturonic acid, trigalacturonic acid, polygalacturonic acid), Arabinoxylan from rice bran, ?-glucan from bakers yeast, D-Ribose or mixtures there-of for inhibiting viral replication in a mammal with a viral disease.
    Type: Application
    Filed: June 21, 2010
    Publication date: July 12, 2012
    Inventors: Klaske Van Norren, Francina Jeannette Dijk, Benjamin Berkhout, Belinda Van't Land Potappel
  • Publication number: 20120034189
    Abstract: The invention provides improved nucleic acids for anti-HIV therapy. The invention further provides selection methods which are capable of predicting already at an early stage of development whether promising anti-pathogenic candidate compounds will be suitable for therapeutic use in vivo.
    Type: Application
    Filed: February 26, 2010
    Publication date: February 9, 2012
    Inventors: Karin J. von Eije, Benjamin Berkhout, Olivier Ter Brake
  • Patent number: 7964406
    Abstract: The invention provides a method for producing a stabilized cell of interest, said method comprising providing a stem cell and/or a precursor cell of said cell of interest with a nucleic acid sequence which, when present in said cell of interest, is capable of stabilizing said cell of interest, providing a non-human animal with said stem cell and/or precursor cell, allowing generation of said cell of interest in said animal, and obtaining said cell of interest. Said animal is preferably provided with a human stem cell and/or human precursor cell, allowing production of a human cell line.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: June 21, 2011
    Assignee: Academisch Medisch Centrum Bij De Universiteit Van Amsterdam
    Inventors: Hergen Spits, Benjamin Berkhout, Jurgen E. Seppen, David M. Markusic, Kees Weijer
  • Publication number: 20100040649
    Abstract: The invention provides improved rtTA and single chain rtTA variants and uses thereof for inducible expression of a nucleic acid of interest. Nucleic acid sequences comprising an improved rtTA and/or sc rtTA sequence according to the invention are also provided, as well as vectors, replicons and cells comprising such nucleic acid sequences.
    Type: Application
    Filed: November 17, 2006
    Publication date: February 18, 2010
    Applicant: Academisch Centrum
    Inventors: Benjamin Berkhout, Atze T. Das
  • Publication number: 20080274991
    Abstract: The invention provides a nucleic acid molecule comprising a sequence that is complementary to a mutant of a genomic nucleic acid sequence of an organism capable of mutating its genome. The genomic nucleic acid sequence preferably comprises a conserved, essential region. Furthermore, the genomic nucleic acid sequence preferably comprises a coding sequence and a DNA/RNA regulatory sequence. A pharmaceutical composition and a gene delivery vehicle comprising a nucleic acid molecule of the invention is also provided, as well as a method for counteracting an organism comprising providing the organism with the nucleic acid molecule. The organism is preferably additionally provided with a nucleic acid sequence complementary to a genomic nucleic acid sequence of the organism.
    Type: Application
    Filed: October 14, 2005
    Publication date: November 6, 2008
    Inventors: Benjamin Berkhout, Olivier Ter Brake
  • Publication number: 20070289029
    Abstract: The invention provides a method for producing a stabilized cell of interest, the method comprising providing a stem cell and/or a precursor cell of the cell of interest with a nucleic acid sequence which, when present in the cell of interest, is capable of stabilizing the cell of interest, providing a non-human animal with the stem cell and/or precursor cell, allowing generation of the cell of interest in said animal, and obtaining said cell of interest. The animal is preferably provided with a human stem cell and/or human precursor cell, allowing production of a human cell line.
    Type: Application
    Filed: August 10, 2005
    Publication date: December 13, 2007
    Inventors: Hergen Spits, Benjamin Berkhout, Jurgen Seppen, David Markusic, Kees Weijer
  • Publication number: 20030099613
    Abstract: An inducible viral replicon comprising at least one inducible repressor and/or activator, and all viral sequences which are essential for replication under direct or indirect control of said inducible repressor and/or activator. The inducible repressor and/or activator may comprise a Tet operon. A replicon of the invention may be used to produce a virus, for instance an attenuated HIV virus, which can be induced to replicate by the presence of doxycycline or a functional analog thereof. The replicon and/or the produced virus may be used to prepare a vaccine, for instance for the prophylaxis of AIDS. A replicon of the invention can be modified, preferably improved, by culturing the replicon in permissive cells for an extended period of time.
    Type: Application
    Filed: March 8, 2002
    Publication date: May 29, 2003
    Inventors: Benjamin Berkhout, Koenraad Dirk Verhoef
  • Patent number: RE49583
    Abstract: Provided is an rtTA and single chain rtTA variants and uses thereof for inducible expression of a nucleic acid of interest. Nucleic acid molecules comprising an improved rtTA and/or sc rtTA sequence according to the invention are also provided, as well as vectors, replicons and cells comprising such nucleic acid molecules.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: July 18, 2023
    Assignee: TET Systems GmbH & Co. KG
    Inventors: Benjamin Berkhout, Atze T. Das